1 |
Abatacept
| 2件: Abatacept Abatacept; Orencia | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
2 |
Alemtuzumab
| 4件: Alemtuzumab Alemtuzumab; Campath; Lemtrada; MABCAMPATH | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 22件: 13 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326 |
3 |
Avacopan
| 1件: Avacopan Avacopan | 1件: D11093
D11093
| 1件: C5AR1 C5AR1 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection 💬 | 3件: 43 43, 44, 222 |
4 |
Azathioprine
| 3件: AZATHIOPRINE AZATHIOPRINE; Azatioprina; Imuran | 2件: D00238
D00238
,
D03033
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
5 |
Belimumab
| 2件: Belimumab Belimumab; Benlysta | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 12件: 11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 |
6 |
Benralizumab
| 2件: Benralizumab Benralizumab; Fasenra | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
7 |
Blisibimod
| 1件: Blisibimod Blisibimod | 1件: D10311
D10311
| - | - | 5件: 43 43, 44, 49, 63, 66 |
8 |
Coenzyme M
| 2件: MESNA MESNA; UROMITEXAN | - | - | - | 11件: 11 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164 |
9 |
Cyclophosphamide
| 6件: Ciclofosfamida Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
10 |
Gusperimus
| 1件: Gusperimus Gusperimus | 1件: D08032
D08032
| - | - | 1件: 44 44 |
11 |
Hydroxychloroquine
| 3件: Hydroxychloroquine Hydroxychloroquine; HYDROXYCHLOROQUINE SULFATE; Plaquenil | 1件: D08050
D08050
| - | - | 27件: 13 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 |
12 |
Mepolizumab
| 2件: MEPOLIZUMAB MEPOLIZUMAB; NUCALA | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 4件: 44 44, 45, 98, 162 |
13 |
Methotrexate
| 6件: Methotrexat Methotrexat; Methotrexate; METHOTREXATE SODIUM; Metoject; METOTREXATO; Méthotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
14 |
Mycophenolate mofetil
| 3件: CELLCEPT CELLCEPT; Mycophenolate Mofetil; Mycophenolate mofetil TEVA | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
15 |
Mycophenolic acid
| 5件: Acido Micofenolico Acido Micofenolico; MICOFENOLICO ACIDO; Mycophenolate; Mycophenolic acid; Myfortic | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
16 |
Naltrexone
| 2件: Naltrexone Naltrexone; Naltrexone Hydrochloride | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
17 |
Prednisolone
| 3件: Prednisolona Prednisolona; Prednisolone; Prednisolonum | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 43件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
18 |
Prednisone
| 3件: Prednisona Prednisona; Prednisone; RAYOS | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
19 |
Reslizumab
| 1件: Reslizumab Reslizumab | 1件: D08985
D08985
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 98 |
20 |
Rituximab
| 6件: MABTHERA MABTHERA; Rituxan; Rituximab; Rixathon; Ruxience; Truxima | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
21 |
Sulfamethoxazole
| 3件: Bactrim Bactrim; Sulfamethoxazole; Sulphamethoxazole | 1件: D00447
D00447
| - | - | 5件: 44 44, 49, 61, 85, 299 |
22 |
Tocilizumab
| 3件: Actemra Actemra; RoActemra; Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
23 |
Tofacitinib
| 4件: Tasocitinib Tasocitinib; Tofacitinib; Xeljanz; Xeljanz XR | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
24 |
Trimethoprim
| 2件: Bactrim Bactrim; Trimethoprim | 2件: D00145
D00145
,
D06236
| - | - | 8件: 36 36, 44, 49, 60, 61, 85, 298, 299 |
25 |
Vilobelimab
| 2件: IFX-1 IFX-1; Vilobelimab | 1件: D11838
D11838
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 43 43, 44, 269 |
26 |
Vitamin D
| 3件: Calciferol Calciferol; Cod liver oil; Vitamin D | - | - | - | 24件: 3 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299 |
27 |
Yellow fever vaccine
| 1件: Yellow fever vaccine Yellow fever vaccine | 1件: D06347
D06347
| - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 |